• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Respiratory

Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

June 9, 2025 By Sean Whooley

Mosanna Therapeutics Logo (1)

Mosanna Therapeutics announced today that it closed an $80 million Series A funding to support its sleep apnea therapy. The Redwood City, California-based company develops an easy-to-use nighttime nasal spray. It aims to treat obstructive sleep apnea by restoring the body’s natural airway control. The therapy could potentially end up offering an alternative to the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Respiratory Tagged With: Mosanna

Phillips Medisize fully integrates Vectura inhaled therapies into business

May 7, 2025 By Sean Whooley

Phillips Medisize Vectura

Phillips Medisize announced that it officially integrated Vectura into its business, expanding its capabilities in inhaled therapies. At the start of the year, the company completed its acquisition of Vectura from a subsidiary of cigarette maker Philip Morris. Vectura enables Phillips Medisize to offer a wider range of formulation, device design, combination product development and manufacturing […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceuticals, Respiratory Tagged With: Phillips-Medisize, Vectura

Qnovia raises $16M to support nicotine inhaler for smoking cessation therapy

December 11, 2024 By Sean Whooley

Qnovia nicotine replacement therapy device

Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform. Blue Ledge Capital, Evolution VC Partners, Vice Ventures and Gaingels led the financing. It brings Richmond, Virginia-based Qnovia to $50 million raised since inception. Funds raised by Qnovia support its proprietary inhaled drug delivery platform, the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Funding Roundup, Respiratory Tagged With: Qnovia

CSA Medical raises $53M to support metered cryospray tech

September 9, 2024 By Sean Whooley

CSA Medical RejuvenAir metered cryospray

CSA Medical announced today that it completed an oversubscribed Series D preferred stock equity financing worth $53 million. TVM Capital Life Science and Yonjin Ventures co-led the funding round. Existing shareholders SV Health Investors, Ascension Ventures, First Analysis, Blue Heron and Intersouth Partners also participated. In connection with the financing, Dr. Luc Marengere of TVM […]

Filed Under: Business/Financial News, Drug-Device Combinations, Funding Roundup, Respiratory Tagged With: CSA Medical

Medline launches new medication delivery nebulizer

May 24, 2024 By Sean Whooley

Medline TurboMist small-volume medication nebulizer

Medline announced that it launched its Hudson RCI TurboMist small-volume nebulizer for delivering medication in respiratory care. TurboMist can deliver medication in just three minutes, making it the fastest small-volume nebulizer on the market, Medline says. Traditional nebulizers, meanwhile, can take at least 10 minutes to provide treatment. Medline designed TurboMist to deliver 2.5 times […]

Filed Under: Drug-Device Combinations, Featured, Respiratory Tagged With: Medline Industries

Qnovia has positive results for inhaled smoking cessation therapy

November 30, 2023 By Sean Whooley

Qnovia nicotine replacement therapy device

Qnovia announced positive results from its first-in-human study for the QN-01 inhaled smoking cessation therapy. Richmond, Virginia-based Qnovia develops the RespiRx drug delivery platform that leverages a vibrating mesh nebulizer. CEO Brian Quigley explained the technology to Drug Delivery Business News last year. The company designed the QN-01 therapy to meet the need for safe and effective […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Respiratory Tagged With: Qnovia

Canadian university set for Phase 2 human trials of inhaled COVID-19 vaccine

January 20, 2023 By Sean Whooley

Researchers at McMaster University in Canada announced that they received $8.2 million from the Canadian Institutes of Health Research (CIHR). Fiona Smaill picked up $8.2 million to advance an inhaled COVID-19 vaccine through to Phase 2 human trials. The trials will evaluate the safety and immunogenicity of the next-generation vaccine delivered by inhaled aerosol. Her […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, McMaster University

Vero Biotech raises $30M for tankless nitric oxide delivery system

January 11, 2023 By Sean Whooley

Vero Biotech Genosyl iNO delivery system

Vero Biotech announced today that it raised $30 million to support its Genosyl inhaled nitric oxide (iNO) delivery system. The financing comes just days after the company received FDA approval for Genosyl. The third-generation Genosyl delivery system features faster dosing, simpler workflow and operational efficiency. Petrichor, a healthcare-dedicated growth capital provider, led the financing. Atlanta-based […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pediatrics, Pharmaceuticals, Respiratory Tagged With: Vero Biotech

How Qnovia aims to use inhaled therapeutics for smoking cessation

October 7, 2022 By Sean Whooley

Qnovia nicotine replacement therapy device

Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery. Brian Quigley spent just over 16 years at tobacco giant Altria. During his time there, he ran two U.S. business units, including the smokeless tobacco business. In July 2020, he joined founder and then-CEO at Qnovia (then […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory Tagged With: Qnovia

Qnovia raises $17M Series A for inhaled therapeutics pipeline

September 28, 2022 By Sean Whooley

Qnovia Logo

Qnovia announced today that it raised $17 million in a Series A financing to support its inhaled therapeutics technologies. Blue Ledge Capital led the offering. DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures also participated. Los Angeles-based Qnovia develops inhaled therapeutics. It focuses on nicotine replacement therapy (NRT) and cardiopulmonary diseases. Qnovia […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory Tagged With: Qnovia

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 28
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS